Cronos Group Future Growth
Future criteria checks 0/6
Cronos Group is forecast to grow earnings and revenue by 8.3% and 4.9% per annum respectively. EPS is expected to decline by 1.4% per annum. Return on equity is forecast to be -7.8% in 3 years.
Key information
8.3%
Earnings growth rate
-1.4%
EPS growth rate
| Pharmaceuticals earnings growth | 21.5% |
| Revenue growth rate | 4.9% |
| Future return on equity | -7.8% |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 126 | -24 | N/A | 17 | 2 |
| 12/31/2025 | 133 | -11 | 4 | 12 | 4 |
| 12/31/2024 | 113 | -29 | -3 | 23 | 6 |
| 9/30/2024 | 111 | -48 | 17 | 28 | N/A |
| 6/30/2024 | 102 | -57 | 11 | 16 | N/A |
| 3/31/2024 | 93 | -54 | -2 | 3 | N/A |
| 12/31/2023 | 87 | -70 | -46 | -43 | N/A |
| 9/30/2023 | 85 | -101 | -86 | -84 | N/A |
| 6/30/2023 | 81 | -133 | -101 | -97 | N/A |
| 3/31/2023 | 84 | -145 | -108 | -103 | N/A |
| 12/31/2022 | 87 | -155 | -94 | -89 | N/A |
| 9/30/2022 | 91 | -213 | -105 | -101 | N/A |
| 6/30/2022 | 91 | -102 | -124 | -119 | N/A |
| 3/31/2022 | 85 | -263 | -147 | -141 | N/A |
| 12/31/2021 | 65 | -127 | -166 | -154 | N/A |
| 9/30/2021 | 66 | -373 | -179 | -156 | N/A |
| 6/30/2021 | 57 | -381 | -181 | -153 | N/A |
| 3/31/2021 | 51 | -310 | -188 | -153 | N/A |
| 12/31/2020 | 47 | -72 | -180 | -145 | N/A |
| 9/30/2020 | 37 | 101 | -185 | -160 | N/A |
| 6/30/2020 | 31 | 636 | -186 | -152 | N/A |
| 3/31/2020 | 29 | 929 | -192 | -155 | N/A |
| 12/31/2019 | 24 | 1,167 | -170 | -131 | N/A |
| 9/30/2019 | 21 | 1,089 | -131 | -59 | N/A |
| 6/30/2019 | 18 | 479 | -130 | -49 | N/A |
| 3/31/2019 | 13 | 293 | -104 | -11 | N/A |
| 12/31/2018 | 12 | -21 | -96 | -8 | N/A |
| 9/30/2018 | 9 | -8 | -103 | -28 | N/A |
| 6/30/2018 | 7 | -1 | N/A | -16 | N/A |
| 3/31/2018 | 5 | -2 | N/A | -13 | N/A |
| 12/31/2017 | 3 | -1 | N/A | -4 | N/A |
| 9/30/2017 | 4 | 1 | N/A | -4 | N/A |
| 6/30/2017 | 2 | 0 | N/A | -8 | N/A |
| 3/31/2017 | 1 | -1 | N/A | -6 | N/A |
| 12/31/2016 | 0 | -1 | N/A | -5 | N/A |
| 9/30/2016 | 2 | 0 | N/A | -3 | N/A |
| 6/30/2016 | 2 | 0 | N/A | -2 | N/A |
| 3/31/2016 | 3 | 1 | N/A | -1 | N/A |
| 12/31/2015 | 2 | 0 | N/A | -1 | N/A |
| 9/30/2015 | 0 | -4 | N/A | -2 | N/A |
| 6/30/2015 | -1 | -4 | N/A | -2 | N/A |
| 3/31/2015 | -1 | -4 | N/A | -2 | N/A |
| 12/31/2014 | -1 | -4 | N/A | -1 | N/A |
| 9/30/2014 | 0 | -2 | N/A | -1 | N/A |
| 6/30/2014 | 0 | -1 | N/A | -1 | N/A |
| 12/31/2013 | 0 | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7CI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 7CI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 7CI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 7CI's revenue (4.9% per year) is forecast to grow slower than the German market (5.6% per year).
High Growth Revenue: 7CI's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7CI is forecast to be unprofitable in 3 years.